# Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based T

Source: https://onco.cc/trials/nct04691817/  
OnCo record `nct04691817` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of atezolizumab and tocilizumab in lung cancer, run by Abramson Cancer Center at Penn Medicine, now recruiting.

## Summary

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy is a phase 1/2, interventional study registered as NCT04691817 by Abramson Cancer Center at Penn Medicine, with a registry enrolment figure of 28 participants, started 2023-07-25 and due to reach its primary completion in 2026-12. Interventions recorded: Atezolizumab; Tocilizumab. Conditions listed: Lung Cancer, Nonsmall Cell. Primary outcome: Overall response rate (ORR). Lung eligibility wording from the registry: "* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04691817
- Phase: 1/2
- Setting: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
- Sponsor: Abramson Cancer Center at Penn Medicine
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT04691817: https://clinicaltrials.gov/study/NCT04691817

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04691817.json